Second annual report from the ISHLT Mechanically Assisted Circulatory Support Registry.

The second annual IMACS registry report includes over 14, 000 patients from 35 countries. Survival, adverse events, and an updated risk model is presented. Continuous flow pumps continue to dominate the world's experience. One and Two-year survival remains at 80% and 70%. Congenital heart disease and biventricular support are the most dominant risk factors. The database is poised for major novel analyses.

[1]  Robert L Kormos,et al.  Eighth annual INTERMACS report: Special focus on framing the impact of adverse events. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  Malcolm E. Turner,et al.  The Decomposition of Time-Varying Hazard into Phases, Each Incorporating a Separate Stream of Concomitant Information , 1986 .

[3]  M. Mehra,et al.  The dawn of the ISHLT Mechanical Assisted Circulatory Support (IMACS) Registry: fulfilling our mission. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  Takeshi Nakatani,et al.  First Annual IMACS Report: A global International Society for Heart and Lung Transplantation Registry for Mechanical Circulatory Support. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  T. Nishinaka,et al.  Japanese registry for Mechanically Assisted Circulatory Support: First report. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  R. Hetzer,et al.  The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European Association for Cardio-Thoracic Surgery (EACTS): second report , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.